DHR Stock Recent News

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #AI--SCIEX announces three software ecosystem enhancements at ASMS, supporting the theme that “all science is data science now.”.

DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient selection and making advanced tests accessible worldwide.

Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered diagnostics This partnership aims to create a framework for rapid diagnostics research, development and commercialization Danaher, through its Centers for Enabling Precision Medicine, will provide support in all aspects of the development cycle across diagnostic modalities WASHINGTON , May 29, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher"), a global science and technology innovator, announced today the launch of a partnership with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize novel diagnostic tools and tests intended to help clinicians better determine which patients would most benefit from precision medicine treatments. "Precision medicines are more targeted than standard therapies and thus require precision diagnostics to determine which patients are most likely to benefit," said Julie Sawyer Montgomery, Danaher Exe

Investors interested in stocks from the Medical Services sector have probably already heard of CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?

Danaher (DHR) reported earnings 30 days ago. What's next for the stock?

DHR gains from strength across its businesses, acquired assets and shareholder-friendly policies. High long-term debt remains concerning.

-- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels believed to be potentially curative --

Danaher Corporation (NYSE:DHR ) BofA Securities 2025 Healthcare Conference May 15, 2025 1:00 PM ET Company Participants Rainer Blair - CEO Conference Call Participants Mike Ryskin - Bank of America Mike Ryskin My name is Mike Ryskin. I'm on the Bank of America Life Science Tools and Diagnostics team and I'm excited to host our next session.

Investors looking for stocks in the Medical Services sector might want to consider either CVS Health (CVS) or Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?

WASHINGTON , May 7, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Thursday, May 15, 2025 at 10:00 a.m.